Abstract | BACKGROUND: METHODS: RESULTS: Systemically administered ANG1005 and Cy5.5Angiopep-2 localised to orthotopic glioma tumours in mice. The glioma transplants correlated with high expression levels of LRP1. Decreasing LRP1 activity, by RNA silencing or LRP1 competitors, decreased uptake of ANG1005 and Angiopep-2 into U87 glioblastoma cells. Conversely, LRP1 expression and endocytosis rates for ANG1005 and Angiopep-2 increased in U87 cells under conditions that mimicked the microenvironment near aggressive tumours, that is, hypoxic and acidic conditions. CONCLUSION:
ANG1005 might be a particularly effective chemotherapeutic agent for the wide array of known LRP1-expressing brain and non- brain cancers, in particular those with an aggressive phenotype.
|
Authors | Y Bertrand, J-C Currie, J Poirier, M Demeule, A Abulrob, D Fatehi, D Stanimirovic, H Sartelet, J-P Castaigne, R Béliveau |
Journal | British journal of cancer
(Br J Cancer)
Vol. 105
Issue 11
Pg. 1697-707
(Nov 22 2011)
ISSN: 1532-1827 [Electronic] England |
PMID | 22027709
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiopep-2
- Low Density Lipoprotein Receptor-Related Protein-1
- Lrp1 protein, mouse
- Peptides
- Receptors, LDL
- Tumor Suppressor Proteins
- paclitaxel-Angiopep-2 conjugate
- Paclitaxel
|
Topics |
- Animals
- Biological Transport
- Blood-Brain Barrier
(metabolism)
- Brain Neoplasms
(drug therapy, metabolism, pathology)
- Cell Line, Tumor
- Endocytosis
- Glioma
(drug therapy, metabolism, pathology)
- Hep G2 Cells
- Humans
- Low Density Lipoprotein Receptor-Related Protein-1
- Male
- Mice
- Mice, Nude
- Paclitaxel
(pharmacokinetics, pharmacology)
- Peptides
(pharmacokinetics, pharmacology)
- Phenotype
- RNA Interference
- Receptors, LDL
(genetics, metabolism)
- Tumor Microenvironment
- Tumor Suppressor Proteins
(genetics, metabolism)
|